SPDR® S&P Biotech ETF (XBI)
Assets
$9.90B
State Street Investment Management
Fee
0.33%
a year
Yield
0.3%
Quarterly
Components
157
top 10: 18%
Performance
The fund's own total return, a year on average over the longer periods; volatility is the yearly standard deviation of its returns.
This year
+17.8%
1 year
+35.2%
3 years
+26.4%
5 years
+3.1%
10 years
+9.7%
Volatility 23.2% over one year, 25.8% over three; Sharpe ratio over three years 0.96.
Largest components
| MRNAModerna Inc | 2.51% | Healthcare | |
| TWSTTwist Bioscience Corp | 1.82% | Healthcare | |
| NTRANatera Inc | 1.81% | Healthcare | |
| HALOHalozyme Therapeutics Inc | 1.74% | Healthcare | |
| BIIBBiogen Inc | 1.73% | Healthcare | |
| ABBVAbbVie Inc | 1.73% | Healthcare | |
| AMGNAmgen Inc | 1.72% | Healthcare | |
| UTHRUnited Therapeutics Corporation | 1.66% | Healthcare | |
| IOVAIovance Biotherapeutics Inc | 1.65% | Healthcare | |
| EXELExelixis Inc | 1.63% | Healthcare |
Sectors
Healthcare96.8%
Financial Services0.6%
Regions
North America92.4%
Europe Developed2.0%
United Kingdom1.2%
Asia Emerging0.0%
Asset classes
Stock US97.7%
Stock non-US3.2%
Cash0.1%
About the fund
- Issuer
- State Street Investment Management
- Since
- 2006-01-31
- Listed on
- NYSE ARCA
- ISIN
- US78464A8707
- Turnover
- 64% a year
In seeking to track the performance of the S&P Biotechnology Select Industry Index (the index), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index (S&P TMI).
From the market data provider's fund data, read 2026-10-19. Returns are the fund's own; past returns say nothing certain about future ones. None of this is advice.